IMMU 140

Drug Profile

IMMU 140

Alternative Names: IMMU-140

Latest Information Update: 10 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immunomedics
  • Class Drug conjugates
  • Mechanism of Action Antigen-presenting-cell-modulators; DNA topoisomerase I inhibitors; HLA-DR antigen modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 18 Jan 2017 Preclinical trials in Solid tumours in USA (Parenteral)
  • 22 Dec 2016 Immunomedics has patent protection for IMMU-140 in USA
  • 06 Dec 2016 Pharmacodynamic results from a preclinical trial in Haematological malignancies presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top